Royalty Pharma plc RPRX

Royalty Pharma demonstrated robust capital allocation in Q3 FY25, deploying $1 billion in royalty transactions, contributing to a year-to-date total of $1.7 billion. Key deals included the acquisition of a royalty interest on Amgen's lung cancer drug, Imdelltra, for up to $950 million, and a funding agreement for Zenas Biopharma's autoimmune drug, obexelimab, for up to $300 million. Post-quarter, the company also acquired a royalty on Alnylam's Amvuttra for $310 million. These transactions highlight Royalty Pharma's strategy of investing in innovative medicines across diverse therapeutic areas.

The company reported strong financial results for Q3 FY25, with both portfolio receipts and royalty receipts growing by 11%. This performance was driven by the diversified portfolio, including key drivers like Voranigo, Tremfya, and the cystic fibrosis franchise. Royalty Pharma achieved a return on invested capital of 15.7% and a return on invested equity of 22.9% for the last 12 months. Reflecting this momentum, the full-year 2025 portfolio receipts guidance was raised for the third time to a range of $3.2 billion to $3.25 billion, representing 14% to 16% growth.

Royalty Pharma's development-stage pipeline has expanded to 17 therapies, with three of the five royalty transactions this year focusing on development-stage assets. This pipeline is projected to generate over $36 billion in cumulative peak sales, translating to over $2 billion in peak royalties for the company. The investment strategy for development-stage assets is highly disciplined, focusing exclusively on Phase III programs with compelling proof-of-concept data and structured deals to mitigate risk, resulting in a 90% success rate for approvals.

The next few years are anticipated to be rich with catalysts from the development-stage pipeline. Six Phase III readouts are expected in Q4 2025 and 2026, including deucrictibant in hereditary angioedema, obexelimab in IgG4-related disease, Novartis' pelacarsen for LP(a), litifilimab in lupus, and aficamten in nonobstructive hypertrophic cardiomyopathy. Several of these assets, particularly daraxonrasib, have multi-blockbuster potential, with peak annual royalties potentially exceeding $200 million. Further pivotal readouts for potential blockbusters like olpasiran, frexalimab, and daraxonrasib in lung cancer are expected in 2027.

Management noted an uptick in biotech M&A activity, viewing it as a positive indicator of the high demand for capital in the life sciences sector, which benefits the royalty market. The company also expressed significant excitement about the China opportunity, identifying it as a new growth avenue for the royalty marketplace. This involves tracking molecules out-licensed from Chinese companies to multinationals as they progress through development, with an expectation of future royalty acquisition opportunities.

Royalty Pharma highlighted its unique structure as an ongoing business, allowing it to invest in and hold long-term royalty assets for 10-15 years or more, unlike many competitors structured as closed-end funds with shorter investment horizons. This perpetual structure, combined with a deep diligence process, enables the company to develop differentiated views on sales trajectories and persistence, leading to attractive investments even in competitive situations, such as the recent Amvuttra royalty acquisition.